重新利用代谢调节剂:抗糖尿病药物作为抗癌剂
Yogita Dhas1, Nupur Biswas2,3, Divyalakshmi M R1
1Rhenix Lifesciences, Hyderabad, 500038, Telangana, India.
Molecular biomedicine
|September 27, 2024
概括
药物再利用探索使用抗糖尿病药物,如甲福明,用于癌症治疗. 虽然有些人表现有希望,但另一些人有混合的结果,需要进一步研究它们的抗癌作用和安全性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- 药物重新定位为传统的癌症药物发现提供了经济高效的替代方案.
- 代谢重编程是癌症的一个关键标志,使代谢调节者成为潜在的治疗点.
- 长期使用的药物,如抗糖尿病药物,由于已确立的安全性,是重新定位的有吸引力的候选药物.
研究的目的:
- 审查当前关于重新使用抗糖尿病药物治疗癌症的见解.
- 评估各种抗糖尿病药物类别的潜在抗癌性质.
- 讨论抗糖尿病药物使用与癌症风险之间的复杂关系.
主要方法:
- 对研究抗糖尿病药物及其对癌症的影响的文献综述.
- 对瘤学中药物再利用的临床前和临床数据的分析.
- 综合有关作用机制和临床结果的信息.
主要成果:
- 甲福明显示出潜在的抗癌特性,包括减少扩散和增强化疗敏感性.
- 硫尿素和 thiazolidinediones (TZDs) 已显示出不一致的抗癌活性.
- -葡萄糖共运输体2 (SGLT2) 抑制剂和二基酶4 (DPP-4) 抑制剂显示出一些前景,而类似葡萄糖素的-1受体激活剂 (GLP-1RA) 则引发了对癌症风险增加的担忧.
结论:
- 抗糖尿病药物对癌症表现出异质的作用,其中甲福明是显著的候选药物.
- 进一步的研究至关重要,以了解机制,并在临床环境中验证这些重用药物的疗效和安全性.
- 对抗糖尿病药物用于癌症治疗的重新定位需要仔细考虑个体药物特征和患者的治疗结果.
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
181
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
181
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:46Electron Transport Chain: Complex I and II
12.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.1K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K